Mast Therapeutics Inc (MSTX)

0.11
AMEX : Health Care
Prev Close 0.11
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.71
Avg Volume 7.98M
Exchange AMEX
Shares Outstanding 211.82M
Market Cap 25.42M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

Conference call scheduled for September 21, 2016 at 8:00am ET

Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care

Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care

Sickle Cell Disease Coalition launches a call to action on neglected disease

MSTX April 2017 Options Begin Trading

MSTX April 2017 Options Begin Trading

Investors in Mast Therapeutics, Inc saw new options become available today, for the April 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health

Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health

Grant will support evaluation of vepoloxamer as an adjuvant agent to thrombolytic therapy for the treatment of acute stroke

Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

Study conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society Of Cardiology 3rd World Congress On Acute Heart Failure

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society Of Cardiology 3rd World Congress On Acute Heart Failure

- Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Very few people expect Mast's compound to become the first, new drug for sickle cell disease in almost 20 years. That's why Mast carries a miniscule $60 million market value.

Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

Study to be conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

-Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

Study met its primary endpoint; AIR001 was generally well-tolerated, with no treatment-related serious adverse events

Mast Therapeutics Provides Business Update

Mast Therapeutics Provides Business Update

- Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016

Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions

Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions

- Repeat administration of vepoloxamer in animals with severe heart failure elicited progressively sustained improvement in left ventricle systolic function evident for at least 6 weeks